Ischemic attack and minor stroke
Drug research and approvals for ischemic attack and minor stroke: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 5 studies of ischemic attack and minor stroke are recruiting on ClinicalTrials.gov, and Health Canada has authorized 9 drug trials for it since 2013.
- Recruiting worldwide: 5
- Trials authorized in Canada: 9
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 5 recruiting on ClinicalTrials.gov ↗- Ambulatory Stroke Unit Treatment for Elderly PatientsNCT07420374 · Not applicable · University Hospital Heidelberg · starts Mar 25, 2026
- Pharmacogenomics in Stroke: Feasibility of CYP2C19 TestingNCT06943586 · Not applicable · University of Alabama at Birmingham · starts Apr 9, 2025
- NORA-HOME: An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic AttacksNCT07500116 · Not applicable · Hospital Universitari Vall d'Hebron Research Institute · starts Jan 29, 2025
- Stroke School -Including Physical Exercise, Patient Education and Individual Follow-up SessionsNCT04945174 · Not applicable · Herlev Hospital · starts Jun 1, 2022
- Microstructure Imaging in Stroke PatientsNCT04118790 · Not reported · Danish Research Centre for Magnetic Resonance · starts Dec 23, 2019
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 14, 2024 | Nuance-icad: effect of genotype-guided oral p2y12 inhibitor selection vs conventional clopidogrel therapy in symptomatic intracranial atherosclerotic disease:…TICAGRELOR | SUNNYBROOK RESEARCH INSTITUTE | Ongoing |
| Jan 9, 2024 | Focal cerebral arteriopathy steroid (focas) trialMETHYLPREDNISOLONE / PREDNISOLONE / PREDNISONE | University of California | Ongoing |
| Jul 12, 2023 | A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to demonstrate the efficacy and safety of milvexian, an oral factor xia…MILVEXIAN (JNJ-70033093, BMS-986177) | Johnson & Johnson | Ongoing |
| Nov 29, 2018 | A global, phase 2, randomized, double-blind, placebo-controlled, response-adaptive dose-ranging study of bms-986177, an oral factor xia inhibitor, for the…MILVEXIAN (BMS-986177) / ACETYLSALICYLIC ACID | Bristol-Myers Squibb | Closed |
| Dec 6, 2017 | A randomised, double-blind, placebo-controlled, international, multicentre, phase III study to investigate the efficacy and safety of ticagrelor and asa…BRILINTA (TICAGRELOR) | AstraZeneca Pharmaceuticals LP | Closed |
| Aug 3, 2016 | Randomized efficacy and safety trial with oral s 44819 after recent ischemic cerebral event international, multi-centre, randomized, double-blind…S44819 | Servier | Ongoing |
| Feb 16, 2016 | Clinical protocol: a phase 2, placebo controlled, randomized, double-blind, parallel-arm study to evaluate efficacy and safety of bms-986141 for the prevention…BMS-986141 | Bristol-Myers Squibb | Pending |
| Mar 18, 2015 | A randomized controlled trial of tnk-tpa versus standard of care for minor ischemic stroke with proven occlusionTNKASE (TENECTEPLASE) | UNIVERSITY OF CALGARY | Ongoing |
| Apr 10, 2013 | Platelet-oriented inhibition in new tia and minor ischemic stroke (point) trial, a randomized, double-blind, multi-center clinical trialCLOPIDOGREL | University of California | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA